Clinical trial
Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)
NCT00043849 · National Institute on Aging (NIA), NIH · Completed
Key facts
| NCT number | NCT00043849 |
|---|---|
| Title | Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) |
| Official title | Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) |
| Lead sponsor | National Institute on Aging (NIA), NIH |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Dementia, Parkinson Disease |
| Intervention type | Drug |
| Interventions | Quetiapine |
| Enrollment | 60 |
| Start date | Jul 1, 2002 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Aug 15, 2002 |
| Last update posted | Dec 11, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: